Thomas Peterffy Biography and Net Worth

Chairman of Atara Biotherapeutics

Mr. Thomas Peterffy is the Chairman of Atara Biotherapeutics. He is 80 years old.

What is Thomas Peterffy's net worth?: The estimated net worth of Thomas Peterffy is at least $16.80 million as of January 27th, 2023. Mr. Peterffy owns 1,630,605 shares of Atara Biotherapeutics stock worth more than $16,795,232 as of December 18th. This net worth estimate does not reflect any other investments that Mr. Peterffy may own. Learn More about Thomas Peterffy's net worth.
How do I contact Thomas Peterffy?: The corporate mailing address for Mr. Peterffy and other Atara Biotherapeutics executives is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. Atara Biotherapeutics can also be reached via phone at (805) 623-4211 and via email at [email protected]. Learn More on Thomas Peterffy's contact information.
Has Thomas Peterffy been buying or selling shares of Atara Biotherapeutics?: Thomas Peterffy has not been actively trading shares of Atara Biotherapeutics in the last ninety days. Learn More on Thomas Peterffy's trading history.
Who are Atara Biotherapeutics' active insiders?: Atara Biotherapeutics' insider roster includes Isaac Ciechanover (CEO), Jakob Dupont (EVP), Matthew Fust (Director), Utpal Koppikar (CFO), K. Murugan (SVP), Joe Newell (Insider), Thomas Peterffy (Chairman), Pascal Touchon (CEO), and Kristin Yarema (Insider). Learn More on Atara Biotherapeutics' active insiders.
Are insiders buying or selling shares of Atara Biotherapeutics?: During the last year, insiders at the biotechnology company sold shares 11 times. They sold a total of 17,499 shares worth more than $204,878.87. The most recent insider tranaction occured on November, 18th when EVP Jill Henrich sold 1,000 shares worth more than $11,200.00. Insiders at Atara Biotherapeutics own 3.7% of the company. Learn More about insider trades at Atara Biotherapeutics.
Information on this page was last updated on 11/18/2024.

Thomas Peterffy Insider Trading History at Atara Biotherapeutics

Thomas Peterffy Buying and Selling Activity at Atara Biotherapeutics

Atara Biotherapeutics Company Overview

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Today's Range

Now: $9.81

$9.68

$10.60

50 Day Range

MA: $10.65

$7.78

$14.26

2 Week Range

Now: $9.81

$6.50

$39.50

Volume

76,980 shs

Average Volume

104,688 shs

Market Capitalization

$56.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55

Uncover the Top Gold Stock of the Bull Market

From Huge Alerts | Ad

Gold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?

Click here to see how this opportunity could transform your portfolio.